Next Article in Journal
Antitumor Activity of the ACC Inhibitor Firsocostat in Breast Cancer Cell Lines: A Proof-of-Concept In Vitro Study
Previous Article in Journal
NRICM102, a TCM Formula, Attenuates COPD-Relevant Inflammatory Lung Injury in Mice by Improving Pulmonary Function and Reversing Immune Dysregulation
Previous Article in Special Issue
Molecular Hybridization of Naphthoquinones and Thiazoles: A Promising Strategy for Anticancer Drug Discovery
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Pharmaceuticals
Volume 19
Issue 2
10.3390/ph19020200
pharmaceuticals-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Disulfiram and Its Derivatives: An Immortal Phoenix of Drug Repurposing

by
Ziad Omran
1,* and
Omeima Abdullah
2
1
King Abdullah International Medical Research Center, King Saud Bin Abdelaziz University for Health Sciences, Jeddah 21423, Saudi Arabia
2
College of Pharmacy, Umm Al-Qura University, Makkah 21955, Saudi Arabia
*
Author to whom correspondence should be addressed.
Pharmaceuticals 2026, 19(2), 200; https://doi.org/10.3390/ph19020200
Submission received: 18 November 2025 / Revised: 7 January 2026 / Accepted: 20 January 2026 / Published: 24 January 2026
(This article belongs to the Special Issue Sulfur-Containing Scaffolds in Medicinal Chemistry)
Browse Figures
Versions Notes

Abstract

Disulfiram (DSF) is a well-established inhibitor of aldehyde dehydrogenases (ALDHs) and an FDA-approved drug for chronic alcoholism. DSF has gained attention as a versatile scaffold for drug repurposing. Its metabolite, diethyldithiocarbamate (DDTC), mediates multiple biological effects via metal chelation and covalent modification of key cysteine residues. Beyond its established anticancer properties, DSF modulates cancer stem cells, reactive oxygen species, proteasome function, and drug-resistance pathways. It also shows promise in metabolic disorders, including type 2 diabetes and obesity, by targeting enzymes such as fructose-1,6-bisphosphatase and α-glucosidase, and influences energy expenditure and autophagy. DSF exhibits antimicrobial and antiparasitic activity, enhances antibiotic efficacy against multidrug-resistant bacteria, and demonstrates antischistosomal and anti-Trichomonas effects, while also providing radioprotective benefits. The clinical translation of DSF is limited by poor solubility, rapid metabolism, and off-target effects; consequently, the development of DSF analogs has become a major focus. Structural optimization has yielded derivatives with improved selectivity, stability, solubility, and target specificity, enabling precise modulation of key enzymes while reducing adverse effects. A key structure-based strategy involves introducing bulkier substituents to exploit differences in ALDH active-site architecture and achieve target selectivity. This concept is exemplified by compounds (1) and (2), in which bulky substituents confer selective inhibition of ALDH1A1 while sparing ALDH2. This review provides a comprehensive overview of DSF analogs, their molecular mechanisms, and therapeutic potential, highlighting their promise as multifunctional agents for cancer, metabolic disorders, infectious diseases, and radioprotection.

1. Introduction

Disulfiram (DSF) is an FDA-approved drug that has been used since 1951 to treat chronic alcoholism and is generally well tolerated. Its primary mechanism of action involves the irreversible inhibition of aldehyde dehydrogenase (ALDH), resulting in the accumulation of acetaldehyde in the bloodstream. This accumulation triggers a series of highly unpleasant physiological reactions, including hypotension, tachycardia, tachypnea, vomiting, and vertigo, when individuals treated with DSF consume even small amounts of alcohol [1].
In recent years, growing evidence has highlighted the potential of repurposing DSF for the treatment of various human cancers. Numerous studies have demonstrated its antitumor effects, particularly when combined with copper (DSF/Cu), in malignancies such as breast cancer [2], liver cancer [3,4], pancreatic cancer [5], glioblastoma [6], neuroblastoma [7], and melanoma [8]. These effects occur through several mechanisms, including the induction of intracellular reactive oxygen species (ROS) [9], activation of various cell death signaling pathways [10,11], inhibition of proteasome activity [12], and suppression of nuclear factor-kappa B signaling [13]. In addition, DSF/Cu targets cancer stem cells [14], providing a novel strategy to prevent tumor recurrence and metastasis [10]. It also interferes with several molecular pathways associated with drug resistance, making it a promising approach to enhance the sensitivity of chemo-resistant and radio-resistant tumors [15]. Currently, DSF is undergoing several clinical trials for different types of cancer, such as metastatic breast cancer, glioblastoma, and recurrent pancreatic carcinoma [16].
In addition to cancer, emerging data support a potential role for DSF in the treatment of inflammatory disorders, such as such as inflammatory bowel disease [17], inflammatory injury of the kidney [18] and liver [19], osteoarthritis [20], and uveitis [21]. Its anti-inflammatory effects are linked to several mechanisms, including the inhibition of pyroptosis through covalent modification of gasdermin D [22] or inactivation of the NOD-like receptor protein 3 inflammasome [23], modulation of intracellular ROS production [23], and suppression of angiogenesis [24].
DSF also shows promising potential for treating metabolic disorders such as type 2 diabetes and obesity. Animal studies have demonstrated that DSF can reduce body weight, improve insulin sensitivity, and reverse obesity-related metabolic dysfunctions [25,26]. The underlying mechanism appears to involve reduced feeding efficiency and increased energy expenditure, potentially mediated through the activation of autophagy [27].
Building on its ability to modulate reactive oxygen species in metabolic pathways, DSF has also demonstrated promising antimicrobial activity. Although it is primarily bacteriostatic against E. coli and S. aureus, DSF significantly enhances the bactericidal activity of antibiotics such as colistin and kanamycin, both in vitro and in murine infection models. Mechanistically, this involves zinc-dependent ROS-mediated disruption of bacterial antioxidant defenses and membrane integrity [28]. Despite the fact that in vivo concentrations of DSF achieved during standard therapy are below its MIC, its synergistic activity with colistin suggests potential clinical relevance as an adjuvant therapy [28]. Recent studies have shown that DSF can also inhibit the metallo-β-lactamase NDM-1 both by coordinating to its zinc ions [29,30] and by carbamylating Cys208 [31]. Additionally, DSF and its metabolites can inactivate NDM-1 by oxidizing the Zn(II)-thiolate in its active site [31], thereby restoring meropenem sensitivity in multidrug-resistant strains. DSF has also been reported to inhibit the phosphoethanolamine transferase MCR-1 via zinc coordination, enhancing colistin-induced membrane damage and resensitizing clinical MCR-1-positive isolates to colistin [30]. These findings highlight the potential of DSF and its metabolites as adjuvants to potentiate existing antibiotics against resistant bacterial strains.

2. Molecular Mechanism of Action

Mechanistically, DSF exerts its pharmacological effects through two distinct mechanisms mediated by its reactive metabolites [32]. The first involves the irreversible carbamoylation of cysteine residues, either catalytic or located near enzymatic catalytic sites. The second is its ability to chelate metal ions, particularly copper, Figure 1.
In vivo, DSF is first reduced into diethyldithiocarbamate (DDTC), which inhibits ALDH in vivo but not in vitro [33], Figure 1A. DDTC is subsequently converted into S-methyl-N,N-diethyldithiocarbamate (Me-DDTC) by hepatic thiol methyltransferases. Oxidation of Me-DDTC by cytochrome P450 yields S-methyl-N,N-diethyldithiocarbamate-sulfoxide (Me-DDTC-SO) and S-methyl-N,N-diethyldithiocarbamate-sulfone (Me-DDTC-SO2). Additionally, Me-DDTC is also metabolized by flavin monooxygenase into S-methyl-N,N-diethyldithiocarbamate-sulfine (Me-DDTC-sulfine), which is further hydrolyzed into S-methyl-N,N-diethylthiocarbamate (Me-DTC) [34]. The latter is then oxidized by cytochrome P450 into S-methyl-N,N-diethylthiocarbamate-sulfoxide (Me-DTC-SO) and S-methyl-N,N-diethylthiocarbamate-sulfone (Me-DTC-SO2).
Among these metabolites, Me-DTC-SO is considered the most stable and is primarily responsible for ALDH2 inhibition, Figure 1B. In contrast, DDTC acts as a potent chelator of transition divalent metal ions, particularly copper [35]. By sequestering essential cofactors, DDTC can disrupt the activity of metal-dependent enzymes such as ALDH [16], Figure 1C.

3. Pharmacokinetics:

DSF is efficiently absorbed after oral dosing, with an estimated bioavailability of 80 to 90 percent. Under the acidic conditions of the stomach, disulfiram is converted into the highly hydrophobic Cu(DDTC)2, which facilitates its absorption across the upper gastrointestinal tract. The high lipid solubility of DSF and its metabolites facilitates their widespread distribution into adipose tissues throughout the body, while their ability to cross the blood–brain barrier enhances distribution within the central nervous system. Human studies indicate half-lives of approximately 7 h for disulfiram and 15 h for DDTC, reflecting substantial inter-subject variability in systemic levels of the drug and its metabolites. Disulfiram metabolites are eliminated through renal, fecal, and pulmonary routes. Renal excretion occurs primarily as glucuronide conjugates of DDTC or as inorganic sulfate, whereas pulmonary elimination involves the release of carbon disulfide. In addition, approximately 20 percent of the intact drug is excreted unchanged in the feces [36,37,38].
Lee et al. reported that the maximum plasma concentration of disulfiram achieved in humans after oral administration of 500 mg, the highest recommended clinical dose, was approximately 0.34 μM [39]. This level is markedly lower than the concentrations commonly used in in vitro experiments, suggesting a discrepancy between experimentally effective concentrations and clinically achievable systemic exposure [32]. This disparity may help explain, at least in part, why many mechanistic effects of disulfiram have not translated into approved therapeutic applications. Collectively, these observations highlight the need for advanced delivery approaches, optimized disulfiram analogs, or prodrug strategies to improve pharmacokinetic performance and enhance translational potential.
In this context, multiple nanodelivery strategies have been developed for DSF. Lipid-based nanoparticles have been shown to enhance systemic availability while reducing toxicity through controlled biodistribution and release. Additionally, other nanoplatforms, such as polymeric nanoparticles, nanofibers, magnetic nanoparticles, quantum dots, and metal–organic frameworks, have been explored to deliver DSF. These systems enable DSF loading via physical adsorption or chemical conjugation and allow controlled drug release in vivo [40,41].

4. Disulfiram Derivatives

Because of its mode of action, DSF can interfere with a wide range of enzymes and physiological pathways [32]. This promiscuity contributes to its diverse side effects, which range from mild to potentially life-threatening, the most notable being the disulfiram–ethanol reaction. Successful treatment requires strict abstinence from alcohol and avoidance of numerous household products containing alcohol, which can be challenging or impractical for many patients. Other adverse effects include hepatotoxicity, peripheral neuropathy, optic neuritis, and psychosis. In addition, disulfiram can increase the toxicity of other drugs by inhibiting cytochrome P450 reductase [16]. Therefore, the development of more selective DSF analogs is needed to achieve specific target modulation while minimizing adverse effects. This section summarizes the DSF analogs reported in the literature and their associated molecular targets.

4.1. ALDH1A1 Inhibitors

A growing body of evidence identifies aldehyde dehydrogenase 1A1 (ALDH1A1) as a key enzyme implicated in multiple pathological conditions. In cancer, its overexpression correlates with poor prognosis, tumor aggressiveness, and drug resistance [42], whereas ALDH1A1 inhibition depletes cancer stem cells and enhances chemosensitivity [43]. In metabolic disorders, ALDH1A1 plays a central role in adipogenesis and glucose metabolism [44,45]; its inhibition reduces body weight and improves insulin sensitivity in animal models [44,46]. In inflammatory diseases, elevated ALDH1A1 expression in intestinal macrophages contributes to the inflammatory phenotype observed in Crohn’s disease [47]. Additionally, ALDH1A1-deficient mice are viable and exhibit no apparent growth or survival defects, supporting the safety of ALDH1A1 inhibition as a therapeutic strategy [48]. Collectively, these findings support ALDH1A1 inhibition as a promising therapeutic strategy for cancer, obesity, diabetes, and inflammation [49]. Therefore, the development of DSF analogs that selectively inhibit ALDH1A1 without affecting ALDH2 is of particular clinical interest, as such compounds could provide therapeutic benefits while minimizing the adverse effects associated with ALDH2 inhibition.
Given that ALDH2 has a narrower substrate tunnel compared to ALDH1A1 [50], bulkier disulfiram derivatives are expected to selectively inhibit ALDH1A1 without affecting ALDH2 activity. Our group has developed series of disulfiram analogs in which two ethyl groups of DSF were replaced by (hetero)aromatic rings, such as p-fluorobenzyl (1) and 3-thienyl (2) derivatives (Figure 2) [51,52,53]. Both compounds exhibited ALDH1A1 inhibition comparable to that of DSF yet were completely devoid of anti-ALDH2 activity [54,55].

4.2. Monoacylglycerol Lipase (MAGL) Inhibitors

MAGL is a serine hydrolase that hydrolyzes monoglycerides into glycerol and free fatty acids [56]. Among its substrates, 2-arachidonoyl glycerol (2-AG) is the most pharmacologically relevant, as it acts as a major endocannabinoid activating both CB1 and CB2 receptors [57], thereby influencing pain sensation [58], addiction [59], neuroprotection [60], and even food intake [61]. MAGL converts 2-AG into arachidonic acid (AA), a precursor of proinflammatory prostaglandins; thus, MAGL inhibition enhances endocannabinoid signaling and reduces eicosanoid synthesis [62]. Inhibition of MAGL has also been linked to beneficial metabolic effects, such as reduced body weight, lower lipid levels [63], and altered insulin secretion [64]. Moreover, MAGL is overexpressed in several aggressive cancers [65], including prostate [66], colorectal [67], liver [68], and nasopharyngeal [69] carcinomas. Taken together, the available evidence supports MAGL inhibition as a promising therapeutic strategy for treating inflammation, neurodegenerative and metabolic disorders, and cancer.
In this context, disulfiram (DSF) has been described as a potent irreversible MAGL inhibitor (IC50 = 1.2 μM), acting through carbamoylation of Cys208 and Cys242 [70], which are located near the enzyme’s active site [71]. Kapanda et al. modified DSF structure to yield compound (3) by replacing the two ethyl group by 4-methyl-1-piperazinyl groups with IC50 of 0.11 μM (Figure 3) [72]. Further pharmacomodulation by the same group, involving the introduction of a 2,4-dinitrophenyl moiety, produced compound (4) (IC50 = 0.16 μM), which was capable of interacting with the catalytic Ser122 residue in addition to Cys208 and Cys242 [73]. Our group also found that introducing hydrophilic substituents into the DSF scaffold, such as hydroxyl (compound 5) or carboxyl (compound 6) groups, slightly enhanced MAGL inhibition, with IC50 values of 0.72 μM and 0.78 μM, respectively (Figure 3) [74].

4.3. DSF Derivatives with Antimicrobial Activity

DSF is a fast-acting bacteriostatic agent with a narrow antibacterial spectrum restricted to Gram-positive bacteria. It inhibits the in vitro growth of methicillin-resistant Staphylococcus aureus (MRSA) in a time- and dose-dependent manner, with a minimum inhibitory concentration (MIC) of 16 μg/mL [75]. DSF suppresses S. aureus growth by disrupting central glucose catabolism and inducing redox imbalance through oxidative stress. Additionally, its metabolite DDTC chelates metal ions and antagonizes the bacterial respiratory chain, leading to metabolic perturbations that further impair cell replication [76]. To enhance the antibacterial potency and metabolic stability of DSF, Long et al. replaced a DDTC moiety by S-alkylthio groups. The resulting n-octyl disulfide derivatives (7) and (8) (Figure 4) exhibited higher activity against MRSA, reduced cytotoxicity toward human hepatocytes, and an extended metabolic half-life [77].
Furthermore, DSF and its S-octyl derivative sensitize S. aureus to the bactericidal effects of fosfomycin [78]. Mechanistic studies revealed that these compounds lower intracellular levels of the fosB cofactor bacillithiol via a thiol–disulfide exchange reaction, thereby depleting the cellular bacillithiol pool required for fosB-mediated fosfomycin inactivation, Figure 5.
DSF’s metabolite Cu(DDTC)2 was reported to inhibit NDM-1 by oxidizing the Zn(II)–thiolate group within its active site [31,80]. However, it did not significantly potentiate the activity of meropenem against E. coli expressing NDM-1, likely due to the poor ability of Cu(DDTC)2 to traverse the stiff outer membrane of E. coli. To enhance the permeability of Cu(DDTC)2 across the bacterial outer membrane, Yang et al. designed a focused library of dithiocarbamate consisting of four series of DDTC analogs with secondary amines (e.g., compound 9), primary amines (e.g., compound 10), hydrazides (e.g., compound 11), and amino acids (e.g., compound 12) [81], Figure 6. They investigated the structure–activity relationships and the influence of physicochemical properties on outer-membrane permeability. This screening identified compound (9) as a highly effective potentiator that restored meropenem activity against clinical NDM-1-producing carbapenem-resistant Enterobacteriaceae and slowed the development of carbapenem resistance. Notably, compound (9) exhibited a fractional inhibitory concentration (FIC) index of 0.02, compared to 0.75 for Cu(DDTC)2, highlighting its markedly superior synergistic effect with meropenem. In vivo experiments further showed that combination therapy with compound (9) and meropenem significantly lowered bacterial loads in the liver and spleen of a mouse infection model and effectively improved survival rates.
Beyond their antibacterial activity, DSF derivatives have also demonstrated potential against protozoan pathogens. Trichomoniasis, the most common non-viral sexually transmitted infection, is caused by the amitochondriate protozoan Trichomonas vaginalis [82]. The rising resistance to the standard drug metronidazole (MTZ) underscores the need for new therapies [83]. Mandalapu et al. developed a library of nitroimidazole–DDTC hybrid derivatives, which exhibited enhanced trichomonicidal activity in vitro against both MTZ-susceptible and MTZ-resistant strains compared to MTZ, while maintaining low cytotoxicity toward HeLa cells [84]. The most potent compound, (13) (Figure 7), showed minimum inhibitory concentrations (MICs) of 8.55 µM and 37.10 µM against MTZ-susceptible and MTZ-resistant strains, respectively, representing 2.4- and 9.8-fold higher potency than MTZ. This improved activity is likely due to the combined effects of the DDTC and 5-nitro groups, which synergistically inhibit hydrogenosomal function and target sulfhydryl groups in the parasite.
DSF and its derivatives have also attracted attention for their potential against helminthic infections. This is particularly relevant for schistosomiasis, a neglected tropical disease that continues to impose a major global health burden [85].
Schistosomiasis affects more than 200 million people each year and is caused by Schistosoma parasites. If left untreated, the disease can be fatal [86,87]. Current treatment options remain extremely limited, relying almost entirely on praziquantel [88] and, to a lesser extent, oxamniquine [89,90]. Dependence on only two drugs raises concerns about the emergence of resistance, creating an urgent need for new therapeutics [91,92]. DSF has shown notable antischistosomal activity against Schistosoma mansoni. In vitro, DSF produced clear effects within a short incubation period at concentrations of 25–50 μM. Treated parasites showed substantial tegumental damage, separation of worm pairs, decreased egg production, impaired motility and vitality, reduced intestinal peristalsis, and, at higher concentrations, parasite death. Male worms were particularly susceptible and displayed severe blister-like tegumental disruptions that progressed to widespread detachment and dissolution [93]. In vivo, DSF treatment reduced mortality by 60 percent in heavily infected mice and decreased granuloma formation by 80 percent, although periportal inflammation remained unchanged [94].
Building on these observations, Rannar and colleagues developed a library of more than 100 DSF derivatives, many of which demonstrated strong in vitro activity against adult S. mansoni [95]. These compounds reduced egg production, impaired pairing stability, and decreased worm vitality and motility. They also caused marked tegumental damage, gut dilatation, and in some cases parasite death. Five derivatives (compounds 14–18) remained active at concentrations as low as 10 μM, Figure 8. Importantly, none of the tested compounds showed cytotoxicity up to 100 μM in two human cell lines [95]. These findings collectively highlight dithiocarbamates as promising candidates for further antischistosomal drug development.

4.4. DSF Derivatives with Antidiabetic Activity

Consistent with the metabolic therapeutic effects of DSF highlighted in the Introduction, recent efforts have focused on its impact on specific enzymes regulating glucose homeostasis, such as fructose-1,6-bisphosphatase (FBPase). FBPase catalyzes the conversion of fructose-1,6-bisphosphate to fructose-6-phosphate and inorganic phosphate and serves as a key rate-limiting enzyme in gluconeogenesis [96]. Due to its central role in glucose production, FBPase represents an attractive drug target [97], as its inhibition can reduce glucose formation from three-carbon precursors without directly affecting glycogenolysis, glycolysis, or the tricarboxylic acid cycle [98]. Huang et al. identified cysteine residue 128 (C128) as a key allosteric site in FBPase [99]. DSF was latter shown to inhibit the enzyme’s catalytic activity by targeting C128, thereby suppressing the gluconeogenesis pathway [100].
Building on this mechanistic insight, disulfiram was structurally optimized through a cyclization strategy to produce compound (19) [100] together with the mixed disulfides 20 and 21 [101]. Compound 19 showed potent FBPase inhibition (IC50 = 0.22 μM), low cytotoxicity in HepG2 cells (IC50 = 75.08 μM), and a moderate hypoglycemic effect in vivo, reducing blood glucose by 54% at 25 mg/kg, Figure 9. In primary mouse hepatocytes, compound (19) suppressed gluconeogenesis and decreased glucose output, consistent with FBPase inhibition. In ICR mice, compound (19) markedly inhibited FBPase, leading to lactate accumulation, and oral glucose tolerance tests indicated moderate improvement in glucose tolerance in both ICR and diabetic db/db mice. These findings underscore the potential of compound 19 as a promising therapeutic candidate for managing type 2 diabetes.
In addition to FBPase, other enzymes involved in type 2 diabetes have been explored as targets for DSF derivatives. Karimov et al. utilized the DDTC scaffold to develop ester derivatives, including compounds (22) and (23), which inhibited α-glucosidase with an IC50 of 28 and 56 µM, surpassing the potency of acarbose (IC50 = 106 µM), a standard clinical glycosidase inhibitor [102] (Figure 10). α-Glucosidase catalyzes the breakdown of complex dietary carbohydrates into simple sugars, so its inhibition slows carbohydrate digestion and absorption, helping to reduce postprandial blood-glucose spikes and offering therapeutic benefit in type 2 diabetes management [103].

4.5. DSF Derivatives with Anticancer Activity

The clinical application of DSF and DDTC as anticancer agents is limited by poor solubility and rapid plasma metabolism [104]. To address these limitations, Najlah et al. designed saccharide-linked DDTC prodrugs, such as compounds (24) and (25) (Figure 11), to improve stability, solubility, and tumor-selective activation. These prodrugs utilize thioglycosidic bonds to protect the DDTC moiety from premature degradation while preserving its metal-chelating ability to generate the active Cu(DDTC)2 complex. They demonstrated potent in vitro cytotoxicity, along with enhanced biostability and solubility [104].
In addition to its anticancer potential, DSF has also been explored in preclinical studies for potential radioprotective effects on healthy tissues [105,106,107]. Wang and colleagues reported piperazine derivatives, compounds (3) and (26) [108] (Figure 12). When administered at a dose of 50 mg/kg, these compounds increased the 30-day survival rate by 50% and 60%, respectively, compared with vehicle-treated mice exposed to a lethal irradiation dose. These findings suggest that selected DSF derivatives may confer protection against radiation-induced damage in normal tissues and warrant further translational evaluation.

5. Conclusions

Disulfiram analogs are promising candidates for drug development, with improved selectivity, potency, and stability compared to the parent compound. By selectively targeting key enzymes and pathways across cancer, metabolic, inflammatory and infectious diseases, these derivatives offer novel therapeutic opportunities. Despite the substantial body of research on disulfiram and its analogs, several critical challenges continue to limit clinical translation. In particular, there remains a clear need for DSF-based agents with enhanced pharmacokinetic stability, reliable bioavailability, and predictable target engagement in vivo. Continued structure-guided optimization and translational studies are expected to advance DSF analogs toward safer and more effective clinical applications.

Funding

This research was funded by King Abdullah International Medical Research Center (KAIMRC), Kingdom of Saudi Arabia, grant number NRC23J/423/05. The authors also acknowledge the support provided by the Research, Development, and Innovation Authority (RDIA), Kingdom of Saudi Arabia, Grant Number: 12840-KSAUHS-2023-KAIMR-R-2-1-HW-.

Data Availability Statement

No new data were created or analyzed in this study.

Conflicts of Interest

The authors declare no conflicts of interest.

References

  1. Bell, R.G.; Smith, H.W. Preliminary report on clinical trials of antabuse. Can. Med. Assoc. J. 1949, 60, 286–288. [Google Scholar]
  2. Yip, N.C.; Fombon, I.S.; Liu, P.; Brown, S.; Kannappan, V.; Armesilla, A.L.; Xu, B.; Cassidy, J.; Darling, J.L.; Wang, W. Disulfiram modulated ROS-MAPK and NFkappaB pathways and targeted breast cancer cells with cancer stem cell-like properties. Br. J. Cancer 2011, 104, 1564–1574. [Google Scholar] [CrossRef]
  3. Chiba, T.; Suzuki, E.; Yuki, K.; Zen, Y.; Oshima, M.; Miyagi, S.; Saraya, A.; Koide, S.; Motoyama, T.; Ogasawara, S.; et al. Disulfiram eradicates tumor-initiating hepatocellular carcinoma cells in ROS-p38 MAPK pathway-dependent and -independent manners. PLoS ONE 2014, 9, e84807. [Google Scholar] [CrossRef] [PubMed]
  4. Li, Y.; Wang, L.H.; Zhang, H.T.; Wang, Y.T.; Liu, S.; Zhou, W.L.; Yuan, X.Z.; Li, T.Y.; Wu, C.F.; Yang, J.Y. Disulfiram combined with copper inhibits metastasis and epithelial-mesenchymal transition in hepatocellular carcinoma through the NF-kappaB and TGF-beta pathways. J. Cell. Mol. Med. 2018, 22, 439–451. [Google Scholar] [CrossRef] [PubMed]
  5. Xu, Y.; Lu, L.; Luo, J.; Wang, L.; Zhang, Q.; Cao, J.; Jiao, Y. Disulfiram Alone Functions as a Radiosensitizer for Pancreatic Cancer Both In Vitro and In Vivo. Front. Oncol. 2021, 11, 683695. [Google Scholar] [CrossRef]
  6. Kannappan, V.; Liu, Y.; Wang, Z.; Azar, K.; Kurusamy, S.; Kilari, R.S.; Armesilla, A.L.; Morris, M.R.; Najlah, M.; Liu, P.; et al. PLGA-Nano-Encapsulated Disulfiram Inhibits Hypoxia-Induced NF-kappaB, Cancer Stem Cells, and Targets Glioblastoma In Vitro and In Vivo. Mol. Cancer Ther. 2022, 21, 1273–1284. [Google Scholar] [CrossRef]
  7. Beaudry, A.; Jacques-Ricard, S.; Darracq, A.; Sgarioto, N.; Garcia, A.; Garcia, T.R.; Lemieux, W.; Beland, K.; Haddad, E.; Cordeiro, P.; et al. Repurposing disulfiram, an alcohol-abuse drug, in neuroblastoma causes KAT2A downregulation and in vivo activity with a water/oil emulsion. Sci. Rep. 2023, 13, 16443. [Google Scholar] [CrossRef]
  8. Wang, Q.; Zhu, T.; Miao, N.; Qu, Y.; Wang, Z.; Chao, Y.; Wang, J.; Wu, W.; Xu, X.; Xu, C.; et al. Disulfiram bolsters T-cell anti-tumor immunity through direct activation of LCK-mediated TCR signaling. EMBO J. 2022, 41, e110636. [Google Scholar] [CrossRef] [PubMed]
  9. Hassani, S.; Ghaffari, P.; Chahardouli, B.; Alimoghaddam, K.; Ghavamzadeh, A.; Alizadeh, S.; Ghaffari, S.H. Disulfiram/copper causes ROS levels alteration, cell cycle inhibition, and apoptosis in acute myeloid leukaemia cell lines with modulation in the expression of related genes. Biomed. Pharmacother. 2018, 99, 561–569. [Google Scholar] [CrossRef]
  10. Zeng, M.; Wu, B.; Wei, W.; Jiang, Z.; Li, P.; Quan, Y.; Hu, X. Disulfiram: A novel repurposed drug for cancer therapy. Chin. Med. J. 2024, 137, 1389–1398. [Google Scholar] [CrossRef]
  11. Abdullah, O.; Beaudoin, C.A.; Omran, Z. Anticancer Effects of New Disulfiram Analogs. Biol. Pharm. Bull. 2024, 47, 1804–1812. [Google Scholar] [CrossRef]
  12. Chen, C.; Nie, D.; Huang, Y.; Yu, X.; Chen, Z.; Zhong, M.; Liu, X.; Wang, X.; Sui, S.; Liu, Z.; et al. Anticancer effects of disulfiram in T-cell malignancies through NPL4-mediated ubiquitin-proteasome pathway. J. Leukoc. Biol. 2022, 112, 919–929. [Google Scholar] [CrossRef]
  13. Xu, B.; Wang, S.; Li, R.; Chen, K.; He, L.; Deng, M.; Kannappan, V.; Zha, J.; Dong, H.; Wang, W. Disulfiram/copper selectively eradicates AML leukemia stem cells in vitro and in vivo by simultaneous induction of ROS-JNK and inhibition of NF-kappaB and Nrf2. Cell Death Dis. 2017, 8, e2797. [Google Scholar] [CrossRef] [PubMed]
  14. Guo, F.; Yang, Z.; Sehouli, J.; Kaufmann, A.M. Blockade of ALDH in Cisplatin-Resistant Ovarian Cancer Stem Cells In Vitro Synergistically Enhances Chemotherapy-Induced Cell Death. Curr. Oncol. 2022, 29, 2808–2822. [Google Scholar] [CrossRef]
  15. Kita, Y.; Hamada, A.; Saito, R.; Teramoto, Y.; Tanaka, R.; Takano, K.; Nakayama, K.; Murakami, K.; Matsumoto, K.; Akamatsu, S.; et al. Systematic chemical screening identifies disulfiram as a repurposed drug that enhances sensitivity to cisplatin in bladder cancer: A summary of preclinical studies. Br. J. Cancer 2019, 121, 1027–1038. [Google Scholar] [CrossRef]
  16. Lanz, J.; Biniaz-Harris, N.; Kuvaldina, M.; Jain, S.; Lewis, K.; Fallon, B.A. Disulfiram: Mechanisms, Applications, and Challenges. Antibiotics 2023, 12, 524. [Google Scholar] [CrossRef]
  17. Bilsel, Y.; Bugra, D.; Yamaner, S.; Bulut, T.; Cevikbas, U.; Turkoglu, U. Could honey have a place in colitis therapy? Effects of honey, prednisolone, and disulfiram on inflammation, nitric oxide, and free radical formation. Dig. Surg. 2002, 19, 306–311; discussion 311–312. [Google Scholar] [CrossRef]
  18. Zhang, Y.; Zhang, R.; Han, X. Disulfiram inhibits inflammation and fibrosis in a rat unilateral ureteral obstruction model by inhibiting gasdermin D cleavage and pyroptosis. Inflamm. Res. 2021, 70, 543–552. [Google Scholar] [CrossRef] [PubMed]
  19. Liu, T.; Wang, P.; Cong, M.; Zhao, X.; Zhang, D.; Xu, H.; Liu, L.; Jia, J.; You, H. Diethyldithiocarbamate, an anti-abuse drug, alleviates steatohepatitis and fibrosis in rodents through modulating lipid metabolism and oxidative stress. Br. J. Pharmacol. 2018, 175, 4480–4495. [Google Scholar] [CrossRef] [PubMed]
  20. Li, C.; Li, L.; Lan, T. Co-treatment with disulfiram and glycyrrhizic acid suppresses the inflammatory response of chondrocytes. J. Orthop. Surg. Res. 2021, 16, 132. [Google Scholar] [CrossRef]
  21. Kanai, K.; Itoh, N.; Yoshioka, K.; Yonezawa, T.; Ikadai, H.; Hori, Y.; Ito, Y.; Nagai, N.; Chikazawa, S.; Hoshi, F.; et al. Inhibitory effects of oral disulfiram on endotoxin-induced uveitis in rats. Curr. Eye Res. 2010, 35, 892–899. [Google Scholar] [CrossRef] [PubMed]
  22. Hu, J.J.; Liu, X.; Xia, S.; Zhang, Z.; Zhang, Y.; Zhao, J.; Ruan, J.; Luo, X.; Lou, X.; Bai, Y.; et al. FDA-approved disulfiram inhibits pyroptosis by blocking gasdermin D pore formation. Nat. Immunol. 2020, 21, 736–745. [Google Scholar] [CrossRef]
  23. Deng, W.; Yang, Z.; Yue, H.; Ou, Y.; Hu, W.; Sun, P. Disulfiram suppresses NLRP3 inflammasome activation to treat peritoneal and gouty inflammation. Free. Radic. Biol. Med. 2020, 152, 8–17. [Google Scholar] [CrossRef]
  24. Li, Y.; Fu, S.Y.; Wang, L.H.; Wang, F.Y.; Wang, N.N.; Cao, Q.; Wang, Y.T.; Yang, J.Y.; Wu, C.F. Copper improves the anti-angiogenic activity of disulfiram through the EGFR/Src/VEGF pathway in gliomas. Cancer Lett. 2015, 369, 86–96. [Google Scholar] [CrossRef]
  25. Omran, Z.; Sheikh, R.; Baothman, O.A.; Zamzami, M.A.; Alarjah, M. Repurposing Disulfiram as an Anti-Obesity Drug: Treating and Preventing Obesity in High-Fat-Fed Rats. Diabetes Metab. Syndr. Obes. 2020, 13, 1473–1480. [Google Scholar] [CrossRef]
  26. Bernier, M.; Mitchell, S.J.; Wahl, D.; Diaz, A.; Singh, A.; Seo, W.; Wang, M.; Ali, A.; Kaiser, T.; Price, N.L.; et al. Disulfiram Treatment Normalizes Body Weight in Obese Mice. Cell Metab. 2020, 32, 203–214.e4. [Google Scholar] [CrossRef] [PubMed]
  27. Bernier, M.; Harney, D.; Koay, Y.C.; Diaz, A.; Singh, A.; Wahl, D.; Pulpitel, T.; Ali, A.; Guiterrez, V.; Mitchell, S.J.; et al. Elucidating the mechanisms by which disulfiram protects against obesity and metabolic syndrome. NPJ Aging Mech. Dis. 2020, 6, 8. [Google Scholar] [CrossRef]
  28. Luo, Q.; Wu, Z.; Pan, Y.; Zhang, Y. Disulfiram inhibits bacterial growth by inducing zinc-dependent reactive oxygen species. Front. Microbiol. 2025, 16, 1619416. [Google Scholar] [CrossRef]
  29. Dubey, V.; Devnath, K.; Gupta, V.K.; Kalyan, G.; Singh, M.; Kothari, A.; Omar, B.J.; Pathania, R. Disulfiram enhances meropenem activity against NDM- and IMP-producing carbapenem-resistant Acinetobacter baumannii infections. J. Antimicrob. Chemother. 2022, 77, 1313–1323. [Google Scholar] [CrossRef] [PubMed]
  30. Chen, C.; Cai, J.; Shi, J.; Wang, Z.; Liu, Y. Resensitizing multidrug-resistant Gram-negative bacteria to carbapenems and colistin using disulfiram. Commun. Biol. 2023, 6, 810. [Google Scholar] [CrossRef]
  31. Chen, C.; Yang, K.W.; Wu, L.Y.; Li, J.Q.; Sun, L.Y. Disulfiram as a potent metallo-beta-lactamase inhibitor with dual functional mechanisms. Chem. Commun. 2020, 56, 2755–2758. [Google Scholar] [CrossRef] [PubMed]
  32. Cvek, B. The Promiscuity of Disulfiram in Medicinal Research. ACS Med. Chem. Lett. 2023, 14, 1610–1614. [Google Scholar] [CrossRef] [PubMed]
  33. Koppaka, V.; Thompson, D.C.; Chen, Y.; Ellermann, M.; Nicolaou, K.C.; Juvonen, R.O.; Petersen, D.; Deitrich, R.A.; Hurley, T.D.; Vasiliou, V. Aldehyde dehydrogenase inhibitors: A comprehensive review of the pharmacology, mechanism of action, substrate specificity, and clinical application. Pharmacol. Rev. 2012, 64, 520–539. [Google Scholar] [CrossRef]
  34. Pike, M.G.; Mays, D.C.; Macomber, D.W.; Lipsky, J.J. Metabolism of a disulfiram metabolite, S-methyl N,N-diethyldithiocarbamate, by flavin monooxygenase in human renal microsomes. Drug Metab. Dispos. Biol. Fate Chem. 2001, 29, 127–132. [Google Scholar]
  35. Heikkila, R.E.; Cabbat, F.S.; Cohen, G. In vivo inhibition of superoxide dismutase in mice by diethyldithiocarbamate. J. Biol. Chem. 1976, 251, 2182–2185. [Google Scholar] [CrossRef]
  36. Gonzalez-Suarez, A.D.; Thorn, C.F.; Whirl-Carrillo, M.; Klein, T.E. PharmGKB summary: Disulfiram pathway. Pharmacogenet. Genom. 2023, 33, 207–216. [Google Scholar] [CrossRef]
  37. Johansson, B. A review of the pharmacokinetics and pharmacodynamics of disulfiram and its metabolites. Acta Psychiatr. Scand. Suppl. 1992, 369, 15–26. [Google Scholar] [CrossRef] [PubMed]
  38. Stokes, M.; Patel, P.; Abdijadid, S. Disulfiram. In StatPearls; StatPearls: Treasure Island, FL, USA, 2025. [Google Scholar]
  39. Lee, S.A.; Elliott, J.H.; McMahon, J.; Hartogenesis, W.; Bumpus, N.N.; Lifson, J.D.; Gorelick, R.J.; Bacchetti, P.; Deeks, S.G.; Lewin, S.R.; et al. Population Pharmacokinetics and Pharmacodynamics of Disulfiram on Inducing Latent HIV-1 Transcription in a Phase IIb Trial. Clin. Pharmacol. Ther. 2019, 105, 692–702. [Google Scholar] [CrossRef]
  40. Huang, D.; Yao, Y.; Lou, Y.; Kou, L.; Yao, Q.; Chen, R. Disulfiram and cancer immunotherapy: Advanced nano-delivery systems and potential therapeutic strategies. Int. J. Pharm. X 2024, 8, 100307. [Google Scholar] [CrossRef]
  41. Lu, Y.; Pan, Q.; Gao, W.; Pu, Y.; Luo, K.; He, B.; Gu, Z. Leveraging disulfiram to treat cancer: Mechanisms of action, delivery strategies, and treatment regimens. Biomaterials 2022, 281, 121335. [Google Scholar] [CrossRef]
  42. Tanei, T.; Morimoto, K.; Shimazu, K.; Kim, S.J.; Tanji, Y.; Taguchi, T.; Tamaki, Y.; Noguchi, S. Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential Paclitaxel and epirubicin-based chemotherapy for breast cancers. Clin. Cancer Res. 2009, 15, 4234–4241. [Google Scholar] [CrossRef]
  43. Vassalli, G. Aldehyde Dehydrogenases: Not Just Markers, but Functional Regulators of Stem Cells. Stem Cells Int. 2019, 2019, 3904645. [Google Scholar] [CrossRef]
  44. Ziouzenkova, O.; Orasanu, G.; Sharlach, M.; Akiyama, T.E.; Berger, J.P.; Viereck, J.; Hamilton, J.A.; Tang, G.; Dolnikowski, G.G.; Vogel, S.; et al. Retinaldehyde represses adipogenesis and diet-induced obesity. Nat. Med. 2007, 13, 695–702. [Google Scholar] [CrossRef] [PubMed]
  45. Omran, Z. Obesity: Current Treatment and Future Horizons. Mini Rev. Med. Chem. 2017, 17, 51–61. [Google Scholar] [CrossRef]
  46. Kiefer, F.W.; Orasanu, G.; Nallamshetty, S.; Brown, J.D.; Wang, H.; Luger, P.; Qi, N.R.; Burant, C.F.; Duester, G.; Plutzky, J. Retinaldehyde dehydrogenase 1 coordinates hepatic gluconeogenesis and lipid metabolism. Endocrinology 2012, 153, 3089–3099. [Google Scholar] [CrossRef] [PubMed]
  47. Sanders, T.J.; McCarthy, N.E.; Giles, E.M.; Davidson, K.L.; Haltalli, M.L.; Hazell, S.; Lindsay, J.O.; Stagg, A.J. Increased production of retinoic acid by intestinal macrophages contributes to their inflammatory phenotype in patients with Crohn’s disease. Gastroenterology 2014, 146, 1278–1288.e2. [Google Scholar] [CrossRef]
  48. Fan, X.; Molotkov, A.; Manabe, S.; Donmoyer, C.M.; Deltour, L.; Foglio, M.H.; Cuenca, A.E.; Blaner, W.S.; Lipton, S.A.; Duester, G. Targeted disruption of Aldh1a1 (Raldh1) provides evidence for a complex mechanism of retinoic acid synthesis in the developing retina. Mol. Cell. Biol. 2003, 23, 4637–4648. [Google Scholar] [CrossRef]
  49. Li, B.; Yang, K.; Liang, D.; Jiang, C.; Ma, Z. Discovery and development of selective aldehyde dehydrogenase 1A1 (ALDH1A1) inhibitors. Eur. J. Med. Chem. 2021, 209, 112940. [Google Scholar] [CrossRef] [PubMed]
  50. Moore, S.A.; Baker, H.M.; Blythe, T.J.; Kitson, K.E.; Kitson, T.M.; Baker, E.N. Sheep liver cytosolic aldehyde dehydrogenase: The structure reveals the basis for the retinal specificity of class 1 aldehyde dehydrogenases. Struct. Fold. Des. 1998, 6, 1541–1551. [Google Scholar] [CrossRef]
  51. Omran, Z. Disulfiram Derivatives as ALDH1A1 and MAGL Inhibitors. U.S. Patent 20230174475 A1, 12 September 2023. [Google Scholar]
  52. Omran, Z.; Abdullah, O. Disulfiram Derivatives as ALDH1A1 and MAGL Inhibitors. U.S. Patent 12227469 B2, 18 February 2025. [Google Scholar]
  53. Omran, Z.; Abdullah, O. Dithienyl disulfiram derivatives as selective aldh1a1 inhibitors. U.S. Patent 12371401 B2, 29 July 2025. [Google Scholar]
  54. Omran, Z. Development of new disulfiram analogues as ALDH1a1-selective inhibitors. Bioorg. Med. Chem. Lett. 2021, 40, 127958. [Google Scholar] [CrossRef]
  55. Omran, Z. Novel Disulfiram Derivatives as ALDH1a1-Selective Inhibitors. Molecules 2022, 27, 480. [Google Scholar] [CrossRef] [PubMed]
  56. Vandevoorde, S.; Saha, B.; Mahadevan, A.; Razdan, R.K.; Pertwee, R.G.; Martin, B.R.; Fowler, C.J. Influence of the degree of unsaturation of the acyl side chain upon the interaction of analogues of 1-arachidonoylglycerol with monoacylglycerol lipase and fatty acid amide hydrolase. Biochem. Biophys. Res. Commun. 2005, 337, 104–109. [Google Scholar] [CrossRef]
  57. Deng, H.; Li, W. Monoacylglycerol lipase inhibitors: Modulators for lipid metabolism in cancer malignancy, neurological and metabolic disorders. Acta Pharm. Sin. B 2020, 10, 582–602. [Google Scholar] [CrossRef]
  58. Calignano, A.; La Rana, G.; Giuffrida, A.; Piomelli, D. Control of pain initiation by endogenous cannabinoids. Nature 1998, 394, 277–281. [Google Scholar] [CrossRef]
  59. Maldonado, R.; Valverde, O.; Berrendero, F. Involvement of the endocannabinoid system in drug addiction. Trends Neurosci. 2006, 29, 225–232. [Google Scholar] [CrossRef]
  60. Sánchez, A.J.; García-Merino, A. Neuroprotective agents: Cannabinoids. Clin. Immunol. 2012, 142, 57–67. [Google Scholar] [CrossRef]
  61. Di Marzo, V.; Goparaju, S.K.; Wang, L.; Liu, J.; Bátkai, S.; Járai, Z.; Fezza, F.; Miura, G.I.; Palmiter, R.D.; Sugiura, T.; et al. Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 2001, 410, 822–825. [Google Scholar] [CrossRef] [PubMed]
  62. Nomura, D.K.; Morrison, B.E.; Blankman, J.L.; Long, J.Z.; Kinsey, S.G.; Marcondes, M.C.; Ward, A.M.; Hahn, Y.K.; Lichtman, A.H.; Conti, B.; et al. Endocannabinoid hydrolysis generates brain prostaglandins that promote neuroinflammation. Science 2011, 334, 809–813. [Google Scholar] [CrossRef] [PubMed]
  63. Douglass, J.D.; Zhou, Y.X.; Wu, A.; Zadroga, J.A.; Gajda, A.M.; Lackey, A.I.; Lang, W.; Chevalier, K.M.; Sutton, S.W.; Zhang, S.P.; et al. Global deletion of MGL in mice delays lipid absorption and alters energy homeostasis and diet-induced obesity. J. Lipid Res. 2015, 56, 1153–1171. [Google Scholar] [CrossRef]
  64. Berdan, C.A.; Erion, K.A.; Burritt, N.E.; Corkey, B.E.; Deeney, J.T. Inhibition of Monoacylglycerol Lipase Activity Decreases Glucose-Stimulated Insulin Secretion in INS-1 (832/13) Cells and Rat Islets. PLoS ONE 2016, 11, e0149008. [Google Scholar] [CrossRef]
  65. Nomura, D.K.; Long, J.Z.; Niessen, S.; Hoover, H.S.; Ng, S.W.; Cravatt, B.F. Monoacylglycerol lipase regulates a fatty acid network that promotes cancer pathogenesis. Cell 2010, 140, 49–61. [Google Scholar] [CrossRef] [PubMed]
  66. Nomura, D.K.; Lombardi, D.P.; Chang, J.W.; Niessen, S.; Ward, A.M.; Long, J.Z.; Hoover, H.H.; Cravatt, B.F. Monoacylglycerol lipase exerts dual control over endocannabinoid and fatty acid pathways to support prostate cancer. Chem. Biol. 2011, 18, 846–856. [Google Scholar] [CrossRef]
  67. Ye, L.; Zhang, B.; Seviour, E.G.; Tao, K.X.; Liu, X.H.; Ling, Y.; Chen, J.Y.; Wang, G.B. Monoacylglycerol lipase (MAGL) knockdown inhibits tumor cells growth in colorectal cancer. Cancer Lett. 2011, 307, 6–17. [Google Scholar] [CrossRef]
  68. Zhang, J.; Liu, Z.; Lian, Z.; Liao, R.; Chen, Y.; Qin, Y.; Wang, J.; Jiang, Q.; Wang, X.; Gong, J. Monoacylglycerol Lipase: A Novel Potential Therapeutic Target and Prognostic Indicator for Hepatocellular Carcinoma. Sci. Rep. 2016, 6, 35784. [Google Scholar] [CrossRef]
  69. Hu, W.R.; Lian, Y.F.; Peng, L.X.; Lei, J.J.; Deng, C.C.; Xu, M.; Feng, Q.S.; Chen, L.Z.; Bei, J.X.; Zeng, Y.X. Monoacylglycerol lipase promotes metastases in nasopharyngeal carcinoma. Int. J. Clin. Exp. Pathol. 2014, 7, 3704–3713. [Google Scholar]
  70. Labar, G.; Bauvois, C.; Muccioli, G.G.; Wouters, J.; Lambert, D.M. Disulfiram is an inhibitor of human purified monoacylglycerol lipase, the enzyme regulating 2-arachidonoylglycerol signaling. Chembiochem 2007, 8, 1293–1297. [Google Scholar] [CrossRef] [PubMed]
  71. Saario, S.M.; Salo, O.M.; Nevalainen, T.; Poso, A.; Laitinen, J.T.; Jarvinen, T.; Niemi, R. Characterization of the sulfhydryl-sensitive site in the enzyme responsible for hydrolysis of 2-arachidonoyl-glycerol in rat cerebellar membranes. Chem. Biol. 2005, 12, 649–656. [Google Scholar] [CrossRef] [PubMed][Green Version]
  72. Kapanda, C.N.; Muccioli, G.G.; Labar, G.; Poupaert, J.H.; Lambert, D.M. Bis(dialkylaminethiocarbonyl)disulfides as potent and selective monoglyceride lipase inhibitors. J. Med. Chem. 2009, 52, 7310–7314. [Google Scholar] [CrossRef]
  73. Kapanda, C.N.; Masquelier, J.; Labar, G.; Muccioli, G.G.; Poupaert, J.H.; Lambert, D.M. Synthesis and pharmacological evaluation of 2,4-dinitroaryldithiocarbamate derivatives as novel monoacylglycerol lipase inhibitors. J. Med. Chem. 2012, 55, 5774–5783. [Google Scholar] [CrossRef]
  74. Omran, Z. New Disulfiram Derivatives as MAGL-Selective Inhibitors. Molecules 2021, 26, 3296. [Google Scholar] [CrossRef]
  75. Long, T.E. Repurposing Thiram and Disulfiram as Antibacterial Agents for Multidrug-Resistant Staphylococcus aureus Infections. Antimicrob. Agents Chemother. 2017, 61, e00898-17. [Google Scholar] [CrossRef]
  76. Long, T.E.; Naidu, S.T.; Hissom, E.G.; Meka, Y.; Chavva, H.; Brown, K.C.; Valentine, M.E.; Fan, J.; Denvir, J.; Primerano, D.A.; et al. Disulfiram induces redox imbalance and perturbations in central glucose catabolism and metal homeostasis to inhibit the growth of Staphylococcus aureus. Sci. Rep. 2025, 15, 15658. [Google Scholar] [CrossRef]
  77. Sheppard, J.G.; Frazier, K.R.; Saralkar, P.; Hossain, M.F.; Geldenhuys, W.J.; Long, T.E. Disulfiram-based disulfides as narrow-spectrum antibacterial agents. Bioorg. Med. Chem. Lett. 2018, 28, 1298–1302. [Google Scholar] [CrossRef] [PubMed]
  78. Lewis, A.D.; Riedel, T.M.; Kesler, M.B.A.; Varney, M.E.; Long, T.E. Pharmacological evaluation of disulfiram analogs as antimicrobial agents and their application as inhibitors of fosB-mediated fosfomycin resistance. J. Antibiot. 2022, 75, 146–154. [Google Scholar] [CrossRef] [PubMed]
  79. Perera, V.R.; Newton, G.L.; Pogliano, K. Bacillithiol: A key protective thiol in Staphylococcus aureus. Expert Rev. Anti-Infect. Ther. 2015, 13, 1089–1107. [Google Scholar] [CrossRef] [PubMed]
  80. Djoko, K.Y.; Achard, M.E.S.; Phan, M.D.; Lo, A.W.; Miraula, M.; Prombhul, S.; Hancock, S.J.; Peters, K.M.; Sidjabat, H.E.; Harris, P.N.; et al. Copper Ions and Coordination Complexes as Novel Carbapenem Adjuvants. Antimicrob. Agents Chemother. 2018, 62, e02280-17. [Google Scholar] [CrossRef]
  81. Chen, C.; Yang, K.W.; Zhai, L.; Ding, H.H.; Chigan, J.Z. Dithiocarbamates combined with copper for revitalizing meropenem efficacy against NDM-1-producing Carbapenem-resistant Enterobacteriaceae. Bioorg. Chem. 2022, 118, 105474. [Google Scholar] [CrossRef]
  82. Schumann, J.A.; Plasner, S. Trichomoniasis. In StatPearls; StatPearls: Treasure Island, FL, USA, 2025. [Google Scholar]
  83. Muzny, C.A.; George, S.; Kissinger, P.J.; Van Gerwen, O.T. Trichomoniasis and Other Sexually Transmitted Parasitic Diseases in Women. Clin. Obstet. Gynecol. 2025, 68, 194–205. [Google Scholar] [CrossRef]
  84. Mandalapu, D.; Kushwaha, B.; Gupta, S.; Singh, N.; Shukla, M.; Kumar, J.; Tanpula, D.K.; Sankhwar, S.N.; Maikhuri, J.P.; Siddiqi, M.I.; et al. 2-Methyl-4/5-nitroimidazole derivatives potentiated against sexually transmitted Trichomonas: Design, synthesis, biology and 3D-QSAR study. Eur. J. Med. Chem. 2016, 124, 820–839. [Google Scholar] [CrossRef]
  85. Hotez, P.J.; Fenwick, A.; Savioli, L.; Molyneux, D.H. Rescuing the bottom billion through control of neglected tropical diseases. Lancet 2009, 373, 1570–1575. [Google Scholar] [CrossRef]
  86. Olveda, D.U.; Olveda, R.M.; McManus, D.P.; Cai, P.; Chau, T.N.; Lam, A.K.; Li, Y.; Harn, D.A.; Vinluan, M.L.; Ross, A.G. The chronic enteropathogenic disease schistosomiasis. Int. J. Infect. Dis. 2014, 28, 193–203. [Google Scholar] [CrossRef]
  87. Vennervald, B.J.; Polman, K. Helminths and malignancy. Parasite Immunol. 2009, 31, 686–696. [Google Scholar] [CrossRef]
  88. Cioli, D.; Pica-Mattoccia, L. Praziquantel. Parasitol. Res. 2003, 90, S3–S9. [Google Scholar] [CrossRef]
  89. Pica-Mattoccia, L.; Carlini, D.; Guidi, A.; Cimica, V.; Vigorosi, F.; Cioli, D. The schistosome enzyme that activates oxamniquine has the characteristics of a sulfotransferase. Memórias Inst. Oswaldo Cruz 2006, 101, 307–312. [Google Scholar] [CrossRef]
  90. Foster, R.; Mesmer, E.T.; Cheetham, B.L.; King, D.F. The control of immature Schistosoma mansoni in mice by UK 3883, a novel 2-aminomethyltetrahydroquinoline derivative. Ann. Trop. Med. Parasitol. 1971, 65, 221–232. [Google Scholar] [CrossRef]
  91. Valentim, C.L.; Cioli, D.; Chevalier, F.D.; Cao, X.; Taylor, A.B.; Holloway, S.P.; Pica-Mattoccia, L.; Guidi, A.; Basso, A.; Tsai, I.J.; et al. Genetic and molecular basis of drug resistance and species-specific drug action in schistosome parasites. Science 2013, 342, 1385–1389. [Google Scholar] [CrossRef] [PubMed]
  92. Botros, S.S.; Bennett, J.L. Praziquantel resistance. Expert Opin. Drug Discov. 2007, 2, S35–S40. [Google Scholar] [CrossRef] [PubMed]
  93. Bennett, J.L.; Gianutsos, G. Disulfiram—A compound that selectively induces abnormal egg production and lowers norepinephrine levels in Schistosoma mansoni. Biochem. Pharmacol. 1978, 27, 817–820. [Google Scholar] [CrossRef] [PubMed]
  94. Seed, J.L.; Pratt, M.C.; Bennett, J.L. The effects of chronic disulfiram treatment on mice infected with Schistosoma mansoni. Am. J. Trop. Med. Hyg. 1979, 28, 508–514. [Google Scholar] [CrossRef]
  95. Rennar, G.A.; Gallinger, T.L.; Mader, P.; Lange-Grunweller, K.; Haeberlein, S.; Grunweller, A.; Grevelding, C.G.; Schlitzer, M. Disulfiram and dithiocarbamate analogues demonstrate promising antischistosomal effects. Eur. J. Med. Chem. 2022, 242, 114641. [Google Scholar] [CrossRef]
  96. Wang, M.; Huang, X.; Zhang, D.; Liu, Y.; Liu, P. The role of fructose-1,6-bisphosphatase 1 on regulating the cancer progression and drug resistance. Discov. Oncol. 2025, 16, 346. [Google Scholar] [CrossRef] [PubMed]
  97. Sawant, S.D.; Sawant, V.N. Comprehensive Review and Perspective on Fructose 1,6-Bisphosphatase Inhibitors for the Management of Type 2 Diabetes Mellitus. Russ. J. Bioorg. Chem. 2025, 51, 439–464. [Google Scholar] [CrossRef]
  98. Kaur, R.; Dahiya, L.; Kumar, M. Fructose-1,6-bisphosphatase inhibitors: A new valid approach for management of type 2 diabetes mellitus. Eur. J. Med. Chem. 2017, 141, 473–505. [Google Scholar] [CrossRef] [PubMed]
  99. Huang, Y.; Wei, L.; Han, X.; Chen, H.; Ren, Y.; Xu, Y.; Song, R.; Rao, L.; Su, C.; Peng, C.; et al. Discovery of novel allosteric site and covalent inhibitors of FBPase with potent hypoglycemic effects. Eur. J. Med. Chem. 2019, 184, 111749. [Google Scholar] [CrossRef]
  100. Xu, Y.X.; Huang, Y.Y.; Song, R.R.; Ren, Y.L.; Chen, X.; Zhang, C.; Mao, F.; Li, X.K.; Zhu, J.; Ni, S.S.; et al. Development of disulfide-derived fructose-1,6-bisphosphatase (FBPase) covalent inhibitors for the treatment of type 2 diabetes. Eur. J. Med. Chem. 2020, 203, 112500. [Google Scholar] [CrossRef]
  101. Huang, Y.; Xu, Y.; Song, R.; Ni, S.; Liu, J.; Xu, Y.; Ren, Y.; Rao, L.; Wang, Y.; Wei, L.; et al. Identification of the New Covalent Allosteric Binding Site of Fructose-1,6-bisphosphatase with Disulfiram Derivatives toward Glucose Reduction. J. Med. Chem. 2020, 63, 6238–6247. [Google Scholar] [CrossRef]
  102. Karimov, A.; Orujova, A.; Taslimi, P.; Sadeghian, N.; Mammadov, B.; Karaman, H.S.; Farzaliyev, V.; Sujayev, A.; Tas, R.; Alwasel, S.; et al. Novel functionally substituted esters based on sodium diethyldithiocarbamate derivatives: Synthesis, characterization, biological activity and molecular docking studies. Bioorg. Chem. 2020, 99, 103762. [Google Scholar] [CrossRef]
  103. Pathak, S.R.; Senwar, K.R.; Ritika; Sharma, K.N. Chapter 4—Alpha-glucosidase in diabetes mellitus. In Diabetes Mellitus; Nidhar, M., Tewari, A.K., Eds.; Academic Press: Cambridge, MA, USA, 2025; pp. 63–78. [Google Scholar]
  104. Najlah, M.; McCallum, N.; Pereira, A.M.; Alves, D.; Ansari-Fard, N.; Rehmani, S.; Kaya, A. Sugar-Linked Diethyldithiocarbamate Derivatives: A Novel Class of Anticancer Agents. Int. J. Mol. Sci. 2025, 26, 5589. [Google Scholar] [CrossRef]
  105. Wang, R.; Shen, J.; Yan, H.; Gao, X.; Dong, T.; Wang, P.; Zhou, J. The Evolving Role of Disulfiram in Radiobiology and the Treatment of Breast Cancer. OncoTargets Ther. 2020, 13, 10441–10446. [Google Scholar] [CrossRef]
  106. Yuan, Q.; Peng, R.; Yu, H.; Wang, S.; Chen, Z.; Dong, S.; Li, W.; Cheng, B.; Jiang, Q.; Cong, Y.; et al. Disulfiram Protects Against Radiation-Induced Intestinal Injury in Mice. Front. Pharmacol. 2022, 13, 852669. [Google Scholar] [CrossRef]
  107. Jia, Y.; Huang, T. Overview of Antabuse((R)) (Disulfiram) in Radiation and Cancer Biology. Cancer Manag. Res. 2021, 13, 4095–4101. [Google Scholar] [CrossRef] [PubMed]
  108. Wang, S.; Ji, Y.; Sun, S.; Liu, Y.; Liu, W.; Long, W. Radiation protective effects of two disulfiram derivatives in mice. Int. J. Radiat. Med. Nucl. Med. 2025, 49, 31–40. [Google Scholar] [CrossRef]
Pharmaceuticals 19 00200 g001
Figure 1. Mechanism of action of DSF. (A) In vivo metabolism of DSF. (B) Carbamoylation of cysteine containing enzymes. (C) Chelation of copper ion by DDTC.
Figure 1. Mechanism of action of DSF. (A) In vivo metabolism of DSF. (B) Carbamoylation of cysteine containing enzymes. (C) Chelation of copper ion by DDTC.
Pharmaceuticals 19 00200 g001
Pharmaceuticals 19 00200 g002
Figure 2. Chemical structures of disulfiram and its analogues (1) and (2), and their half-maximal inhibitory concentration (IC50) against ALDH1A1 and ALDH2.
Figure 2. Chemical structures of disulfiram and its analogues (1) and (2), and their half-maximal inhibitory concentration (IC50) against ALDH1A1 and ALDH2.
Pharmaceuticals 19 00200 g002
Pharmaceuticals 19 00200 g003
Figure 3. Chemical structure of MAGL inhibitors 3–6.
Figure 3. Chemical structure of MAGL inhibitors 3–6.
Pharmaceuticals 19 00200 g003
Pharmaceuticals 19 00200 g004
Figure 4. Chemical structure disulfide derivatives 7 and 8.
Figure 4. Chemical structure disulfide derivatives 7 and 8.
Pharmaceuticals 19 00200 g004
Pharmaceuticals 19 00200 g005
Figure 5. (A) Mechanism of fosfomycin inactivation by bacillithiol [79], (B) Mechanism of bacillithiol-disulfide exchange reaction with Compound (8) [78].
Figure 5. (A) Mechanism of fosfomycin inactivation by bacillithiol [79], (B) Mechanism of bacillithiol-disulfide exchange reaction with Compound (8) [78].
Pharmaceuticals 19 00200 g005
Pharmaceuticals 19 00200 g006
Figure 6. Chemical structures of Cu(DDTC)2 and its analogs (9–12) as inhibitors of NDM-1 and their FIC indices against NDM1-producing E. coli BL21.
Figure 6. Chemical structures of Cu(DDTC)2 and its analogs (9–12) as inhibitors of NDM-1 and their FIC indices against NDM1-producing E. coli BL21.
Pharmaceuticals 19 00200 g006
Pharmaceuticals 19 00200 g007
Figure 7. Chemical structure of the anti-Trichomonas vaginalis compound (13).
Figure 7. Chemical structure of the anti-Trichomonas vaginalis compound (13).
Pharmaceuticals 19 00200 g007
Pharmaceuticals 19 00200 g008
Figure 8. Representative structures of selected disulfiram-derived dithiocarbamate compounds with antischistosomal activity against Schistosoma mansoni.
Figure 8. Representative structures of selected disulfiram-derived dithiocarbamate compounds with antischistosomal activity against Schistosoma mansoni.
Pharmaceuticals 19 00200 g008
Pharmaceuticals 19 00200 g009
Figure 9. Chemical structures of FBPase inhibitors 19–21.
Figure 9. Chemical structures of FBPase inhibitors 19–21.
Pharmaceuticals 19 00200 g009
Pharmaceuticals 19 00200 g010
Figure 10. Chemical structures of α-glucosidase inhibitors 22 and 23.
Figure 10. Chemical structures of α-glucosidase inhibitors 22 and 23.
Pharmaceuticals 19 00200 g010
Pharmaceuticals 19 00200 g011
Figure 11. Chemical structures of DDTC prodrugs 24 and 25.
Figure 11. Chemical structures of DDTC prodrugs 24 and 25.
Pharmaceuticals 19 00200 g011
Pharmaceuticals 19 00200 g012
Figure 12. Chemical structures of DDTC piperazine derivatives 3 and 26 with radioprotective effects.
Figure 12. Chemical structures of DDTC piperazine derivatives 3 and 26 with radioprotective effects.
Pharmaceuticals 19 00200 g012
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Omran, Z.; Abdullah, O. Disulfiram and Its Derivatives: An Immortal Phoenix of Drug Repurposing. Pharmaceuticals 2026, 19, 200. https://doi.org/10.3390/ph19020200

AMA Style

Omran Z, Abdullah O. Disulfiram and Its Derivatives: An Immortal Phoenix of Drug Repurposing. Pharmaceuticals. 2026; 19(2):200. https://doi.org/10.3390/ph19020200

Chicago/Turabian Style

Omran, Ziad, and Omeima Abdullah. 2026. "Disulfiram and Its Derivatives: An Immortal Phoenix of Drug Repurposing" Pharmaceuticals 19, no. 2: 200. https://doi.org/10.3390/ph19020200

APA Style

Omran, Z., & Abdullah, O. (2026). Disulfiram and Its Derivatives: An Immortal Phoenix of Drug Repurposing. Pharmaceuticals, 19(2), 200. https://doi.org/10.3390/ph19020200

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop